To include your compound in the COVID-19 Resource Center, submit it here.

Axovant discontinuing intepirdine for AD after Phase III miss

Axovant Sciences Ltd. (NYSE:AXON) said it will discontinue development of intepirdine (RVT-101) to treat mild to moderate Alzheimer’s disease after the product missed the co-primary endpoints in the Phase

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE